NCT05252416 2025-11-28(VELA) Study of BLU-222 in Advanced Solid TumorsBlueprint Medicines CorporationPhase 1 Terminated50 enrolled
NCT05238831 2024-01-23SMMART Adaptive Clinical Treatment (ACT) TrialOHSU Knight Cancer InstitutePhase EARLY_PHASE1 Withdrawn
NCT05905341 2023-11-08Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.PfizerPhase 1 Withdrawn